EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Weight management with orlistat in type 2 diabetes: an electronic health records study

Shraboni Ghosal iD, Neil Heron iD, Kayleigh J Mason iD, James Bailey iD, Kelvin P Jordan iD

British Journal of General Practice · 2024

DOI: 10.3399/bjgp.2023.0684 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of General Practice, 2024. Verfasst von Shraboni Ghosal und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Keele University, Keele; research associate (postdoctoral), School of Health Sciences, University of Manchester, Manchester. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Orlistat, Anti-Obesity Agents, Weight Loss. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Orlistat is recommended as an adjunct to diet and exercise for weight loss in the treatment of type 2 diabetes mellitus (T2DM).

Aim

To explore associations between patient characteristics and orlistat prescribing, and to determine associations of orlistat with weight loss in T2DM and prediabetes. Design and setting Cohort study using anonymised health records from a UK database of general practice.

Method

The UK Clinical Practice Research Datalink (CPRD) Aurum database was searched to compile a cohort of patients aged ≥18 years, first diagnosed with T2DM or prediabetes in 2016 or 2017. Once the data had been collated, multivariable logistic regression models were used to determine associations with starting orlistat and stopping it early (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2OrlistatAnti-Obesity AgentsWeight LossElectronic Health RecordsPrediabetic StateHumansFemaleMaleMiddle AgedObesityUnited KingdomAgedAdultHypoglycemic AgentsCohort StudiesPractice Patterns, Physicians'

Stichwörter der Autor:innen

body mass indexobesityprediabetesprimary caretype 2 diabetesweight loss

Substanzen

OrlistatAnti-Obesity AgentsHypoglycemic Agents

Autor:innen und Institutionen

  • School of Medicine, Keele University, Keele; research associate (postdoctoral), School of Health Sciences, University of Manchester, Manchester.
  • School of Medicine, Keele University, Keele; clinical lecturer, Centre for Public Health, Queen's University Belfast, Belfast.
  • School of Medicine, Keele University, Keele.

ORCID-Profile: Shraboni Ghosal, Neil Heron, Kayleigh J Mason, James Bailey, Kelvin P Jordan

Zitieren

APA

Ghosal, S., Heron, N., Mason, K. J., Bailey, J., & Jordan, K. P. (2024). Weight management with orlistat in type 2 diabetes: an electronic health records study. British Journal of General Practice. https://doi.org/10.3399/bjgp.2023.0684

Vancouver

Ghosal S, Heron N, Mason KJ, Bailey J, Jordan KP. Weight management with orlistat in type 2 diabetes: an electronic health records study. British Journal of General Practice. 2024. doi:10.3399/bjgp.2023.0684

BibTeX
@article{Ghosal2024,
  author = {Ghosal, Shraboni and Heron, Neil and Mason, Kayleigh J and Bailey, James and Jordan, Kelvin P},
  title = {Weight management with orlistat in type 2 diabetes: an electronic health records study},
  journal = {British Journal of General Practice},
  year = {2024},
  doi = {10.3399/bjgp.2023.0684}
}
Kostenlos starten →